ESTRO 2025 - Abstract Book

S1110

Clinical – Head & neck

ESTRO 2025

4020

Digital Poster Prognostic factors and outcomes in oral cavity cancer patients:

Carlota Cascajares Sanz, Raquel Benlloch Rodríguez, Sofía Santana Jiménez, María Hernández Miguel, Marta López Valcárcel, Sofía Merino Pedraza, Jose Cantillana Barrenas, Arancha Gallego Barranco, Jesús Romero Fernández, Mariela Rojas Quesada, Susana Sánchez Rico, Sofía Córdoba Largo, Beatriz Gil Haro, María Ángeles Ruiz Rodríguez, Joaquin Velasco Jiménez, Cristina de la Fuente Alonso, Irma Zapata Paz, Sara Pérez Mata, Francisco Javier Martinez Paredes Radiotherapy oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain Purpose/Objective: To analyze the interval between surgery and radiotherapy (SRI) and overall treatment time (OTT) in oral cavity cancer (OCC) patients. Secondary objectives were defined as: overall survival (OS), local relapse free survival (LRFS), nodal relapse free survival (NRFR), distant metastasis free survival (DMFS), and prognostic factors. Material/Methods: We retrospectively analyzed 51 patients (p.) with epidermoid OCC treated between 2015-2022. Mean age was 65 years (23-90); the ratio males/females was 23/28. Pathological stage: I: 1 patient (2%), II: 7 patients (13.7%), III:14 patients (27.5), IVA: 24 patients (471%), IVB: 5 patients (9.8%). Treatment technique: IMRT-IGRT; mean dose 67Gy; 1.6-2.16Gy/fraction. Concomitant cisplatin (63%). According to literature we defined high risk (HR) patients as those with extranodal extension (ENE) and/or positive microscopic margin (R1). Statistics: Chi-Square, Kapplan-Meier, Log Rank. Results: Median follow-up was 39 months (1-99). Mean SRI: 69 days (25-181). Mean OTT: 48 days (40-61). OS, LRFS and NRFR were not influenced by SRI-(figure1). Larger SRI had higher risk of distant metastasis (81,25 vs 65,25 days; p= 0,027). OTT was not statistically significant. HR patients had poorer OS rate (67% vs 28%;p=0,02)-(figure2) and a non significant trend towards local relapse (42% vs 18%; p=0,099). 5-year OS, LRFS, NRFR and DMFS were 53%, 70%, 85% and 71% respectively. 5-year OS was worse in R1 (25% vs 66%; p=0,005) and HR (60% vs 33%;p=0,018). 5-year LRFS was worse in R1 (75% vs 37%; p=0,001). There was a trend towards worse 5-year LRFS for IVB (27% vs 56%,91%,70% for stages II, III and IVA respectively; p=0,091), and for perineural infiltration (72% vs 59%; p=0,09).